ANDA Litigation Settlements

Summer 2018

GENERICally Speaking: A Hatch Waxman Litigation Bulletin
Case Name Drug Patent No(s). Publicly Available Terms
AstraZeneca AB v. Mylan Pharms. Inc., 17-1778 (Fed. Cir.) Onglyza® (saxagliptin HCl tablets)
Kombiglyze XR™ (saxagliptin HCl / metformin HCl extended-release tablets)
RE44,186 The Federal Circuit granted a joint motion by the parties to voluntarily drop the appeal with each side bearing its own fees and costs.
The district court concluded that patent-in-suit claims were non-obviousness.

Related Publications

Second Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
June 25, 2024
Amarin Pharma, Inc. v. Hikma Pharms. USA Inc.
GENERICally Speaking Hatch Waxman Bulletin
June 10, 2024
Teva Branded Pharm. Products R&D, Inc. v. Amneal Pharms. of NY, LLC
GENERICally Speaking Hatch Waxman Bulletin
April 30, 2024
Pharmacyclics LLC v. Alvogen Pine Brook LLC
GENERICally Speaking Hatch Waxman Bulletin
First Quarter
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Oren Langer, Christopher Pinahs, Emily Tremblay, and Christine May
Back to Top